Page 44 - Bio Developments News Today

Valneva and Pfizer have initiated a Phase 2 study for their Lyme disease vaccine candidate: which is the only active Lyme disease vaccine in clinical development today.

The 2020 Pfizer/BioNTech COVID-19 vaccine trial recruited more than 44,000 participants and reached submission for emergency authorization in 248 days: showing unprecedented speed and agility in the context of a global pandemic. So what have been the learnings from the trial – and how could they be applied to vaccine development in the future?

Moderna’s variant-specific vaccine – designed to tackle the South Africa variant – has been shipped to the US National Institutes of Health (NIH) for a Phase 1 clinical trial.

Coming of Phage: Clinical trial underscores safety of technology battling E. coli triggered UTIs Locus Biosciences says the results of its early stage clinical trial for CRISPR-enhanced bacteriophage therapy shows its precision medicine asset is safe and well tolerated. Announcing the completion of its Phase 1b study of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage (crPhage) product targeting Escherichia coli (E. coli) ​bacteria that cause urinary tract infection...

Moderna has announced new capital investments to increase COVID-19 vaccine manufacturing capacity: targeting global capacity of 1.4 billion doses in 2022.

Real-world data from England shows that the Pfizer/BioNTech vaccine offers 'clear protection from first dose' and may help interrupt transmission; while Scottish data shows the first doses of vaccines led to a substantial fall in hospital admissions.

Sanofi and GSK have initiated a new Phase 2 study for their COVID-19 vaccine candidate; with a Phase 3 study set to follow in Q2 and potential rollout of the vaccine in Q4.

Sanofi to help manufacture Janssen COVID-19 vaccine Sanofi’s vaccine manufacturing plant in Marcy l’Etoile, France, will formulate and fill vials of Janssen’s COVID-19 vaccine: producing around 12 million doses a month to help address global supply demands. Situated outside of Lyon, Sanofis facility covers vaccine research, development and production. It produces vaccines against diseases such as diphtheria, typhoid, tetanus, polio and whooping cough.  Sanofis...

Human B cells continue to work against SARS-CoV-2 months after infection, but derived antibodies do not recognize mutant variants from Brazil and South Africa, finds new research published in Science Immunology.

Pfizer and BioNTech have submitted new stability data to the US Food and Drug Administration (FDA), showing that their vaccine can be stored at standard freezer temperatures for two weeks.